Esperion Therapeutics (ESPR) Financial Statements & Analysis

Esperion Therapeutics (ESPR) Income Statement

Esperion Therapeutics reported revenue of $403.13M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 21.3% from $332.31M a year earlier. Esperion Therapeutics posted a net loss of $22.68M, compared with a net loss of $51.74M a year earlier. Gross margin was 67.9% and operating margin 15.0%. In the most recent quarter, Q1 fiscal 2026 (ended Mar 31, 2026), revenue was $80.10M, up 23.2% from the same quarter a year earlier.

Esperion Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Esperion Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	403.14	332.31	116.33	75.48	78.45	227.55	148.36	184.47	0.00
Cost of Revenue	129.22	114.84	43.27	145.89	14.22	2.39	0.00	0.27	0.26
Gross Profit	273.91	263.71	73.07	48.51	64.23	225.16	148.36	184.21	-0.26
Operating Expenses
Research & Development	47.85	46.24	86.11	118.93	105.98	146.94	175.61	171.49	147.60
Selling, General & Administrative	165.79	163.07	142.52	109.08	184.99	199.62	65.85	33.10	21.38
Operating Expenses	213.64	209.31	228.63	228.01	290.96	346.55	241.47	204.59	168.98
Operating Income	60.27	54.40	-155.56	-179.50	-226.73	-121.40	-93.10	-204.59	-168.98
Other Income/Expense
Interest Income	3.50	7.60	4.40	2.40	0.00	0.00	0.00	0.00	0.00
Interest Expense	84.60	-59.25	58.98	-56.81	46.35	22.67	8.12	0.10	0.20
Other Income/Expense	3.49	-106.15	5.29	-54.16	3.98	-22.16	-4.06	2.78	1.99
Income
Income Before Tax	-20.84	-51.75	-209.25	-233.66	-269.11	-143.55	-97.17	-201.81	-166.99
Income Tax Expense	1.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-22.68	-51.75	-209.25	-233.66	-269.11	-143.55	-97.17	-201.81	-166.99
Net Income - Continuous Operations	-22.68	-51.75	-209.25	-233.66	-269.11	-143.55	-97.17	-201.81	-166.99
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	63.87	54.47	-150.11	-179.00	-222.14	-120.33	-88.73	-204.32	-166.53
EBIT	63.76	54.40	-150.27	-179.50	-222.76	-121.40	-	-	-
Depreciation & Amortization	0.11	0.06	0.16	0.50	0.61	0.55	0.32	0.27	0.26
Earnings Per Share
Basic EPS	-	-	-2.00	-4.00	-9.00	-6.00	-4.00	-8.00	-7.00
Diluted EPS	-	-	-2.00	-4.00	-9.00	-6.00	-4.00	-8.00	-7.00
Basic Shares Outstanding	207.87	187.18	103.11	66.41	28.90	27.47	27.09	26.75	23.93
Diluted Shares Outstanding	207.87	187.18	103.11	66.41	28.90	27.47	27.09	26.75	23.93

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Esperion Therapeutics Financial Statements

What was Esperion Therapeutics's revenue in fiscal 2025?

Esperion Therapeutics reported revenue of $403.13M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 21.3% from $332.31M a year earlier.

Is Esperion Therapeutics profitable?

No. Esperion Therapeutics reported a net loss of $22.68M in fiscal 2025. In fiscal 2024 it lost $51.74M.

What is Esperion Therapeutics's operating margin?

Esperion Therapeutics's operating income was $60.27M on revenue of $403.13M in fiscal 2025, an operating margin of 15.0%, compared with 16.4% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition